Karyopharm Therapeutics (NASDAQ:KPTI) Cut to Hold at ValuEngine

Share on StockTwits

ValuEngine downgraded shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a buy rating to a hold rating in a research note released on Thursday, ValuEngine reports.

KPTI has been the subject of several other research reports. Robert W. Baird reiterated an outperform rating and set a $25.00 price target (up previously from $15.00) on shares of Karyopharm Therapeutics in a research report on Friday, July 5th. HC Wainwright reiterated a buy rating and set a $48.00 price target (down previously from $52.00) on shares of CELYAD SA/ADR in a research report on Friday, July 5th. Zacks Investment Research cut shares of ExlService from a hold rating to a sell rating in a research report on Wednesday. Wedbush set a $11.00 price target on shares of Sangamo Therapeutics and gave the stock a hold rating in a research report on Monday, July 8th. Finally, BidaskClub upgraded shares of Zumiez from a sell rating to a hold rating in a research report on Saturday, June 22nd. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of Hold and an average price target of $17.41.

Shares of NASDAQ:KPTI opened at $8.03 on Thursday. Karyopharm Therapeutics has a one year low of $3.92 and a one year high of $21.71. The business’s 50 day simple moving average is $6.37. The company has a quick ratio of 6.19, a current ratio of 6.19 and a debt-to-equity ratio of 0.98.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.25). Karyopharm Therapeutics had a negative return on equity of 119.66% and a negative net margin of 1,005.85%. The business had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.75 million. As a group, equities research analysts forecast that Karyopharm Therapeutics will post -3.79 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the stock. Two Sigma Investments LP boosted its stake in Karyopharm Therapeutics by 53.2% during the 4th quarter. Two Sigma Investments LP now owns 611,153 shares of the company’s stock worth $5,727,000 after acquiring an additional 212,196 shares during the last quarter. FMR LLC boosted its stake in Karyopharm Therapeutics by 51.5% during the 4th quarter. FMR LLC now owns 1,875,140 shares of the company’s stock worth $17,570,000 after acquiring an additional 637,357 shares during the last quarter. Deutsche Bank AG lifted its stake in Karyopharm Therapeutics by 79.1% in the fourth quarter. Deutsche Bank AG now owns 479,323 shares of the company’s stock valued at $4,489,000 after buying an additional 211,764 shares in the last quarter. Premier Asset Management LLC bought a new position in Karyopharm Therapeutics in the fourth quarter valued at approximately $282,000. Finally, First Midwest Bank Trust Division lifted its stake in Karyopharm Therapeutics by 259.2% in the first quarter. First Midwest Bank Trust Division now owns 610,850 shares of the company’s stock valued at $3,567,000 after buying an additional 440,769 shares in the last quarter. 84.20% of the stock is currently owned by institutional investors and hedge funds.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme.

Recommended Story: What is the NASDAQ Stock Market?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.